4//SEC Filing
Coherus BioSciences, Inc. 4
Accession 0000899243-16-026739
$CHRSCIK 0001512762operating
Filed
Aug 9, 8:00 PM ET
Accepted
Aug 10, 4:05 PM ET
Size
16.0 KB
Accession
0000899243-16-026739
Insider Transaction Report
Form 4
Watler Peter K.
Chief Technical Officer
Transactions
- Sale
Common Stock, $0.0001 par value
2016-08-08$30.00/sh−40,000$1,200,016→ 0 total - Sale
Common Stock, $0.0001 par value
2016-08-08$30.00/sh−15,621$468,649→ 0 total(indirect: By Spouse) - Exercise/Conversion
Stock Option (right to buy)
2016-08-08−15,621→ 14,373 total(indirect: By Spouse)Exercise: $2.50Exp: 2024-06-29→ Common Stock (15,621 underlying) - Exercise/Conversion
Common Stock, $0.0001 par value
2016-08-08$2.08/sh+40,000$83,352→ 40,000 total - Exercise/Conversion
Common Stock, $0.0001 par value
2016-08-08$2.50/sh+15,621$39,060→ 15,621 total(indirect: By Spouse) - Exercise/Conversion
Stock Option (right to buy)
2016-08-08−40,000→ 48,503 totalExercise: $2.08Exp: 2022-12-13→ Common Stock (40,000 underlying)
Footnotes (6)
- [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The transaction was executed in multiple trades in prices ranging from $30.00 to $30.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- [F3]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's wife.
- [F4]The transaction was executed in multiple trades in prices ranging from $30.00 to $30.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- [F5]All shares underlying this option are vested and exercisable as of the date hereof.
- [F6]A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from May 29, 2014, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Documents
Issuer
Coherus BioSciences, Inc.
CIK 0001512762
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001512762
Filing Metadata
- Form type
- 4
- Filed
- Aug 9, 8:00 PM ET
- Accepted
- Aug 10, 4:05 PM ET
- Size
- 16.0 KB